AI assistant
Novacyt — Share Issue/Capital Change 2016
Aug 31, 2016
1557_dva_2016-08-31_4ddabf03-bb2f-4b91-9013-f5395e8d4e42.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
NOVACYT SHARE CAPITAL UPDATE
Paris, France and Cambridge, UK – 31st August 2016 – Novacyt (ALTERNEXT: ALNOV), an international clinically focused diagnostics company, today announces the conversion of 15 convertible bond units from tranches five and six of the flexible bond financing agreement concluded on 31st July, 2015 with YA II PN, Ltd (formerly YA Global Master SPV Ltd), a fund managed by Yorkville Advisors LLC.
The draw-down of tranches five and six dated 2 nd August, 2016 resulted in the issuance of 50 convertible bond units each of which have the equivalent nominal share value of €10,000 and carry a total of 181,818 subscription warrants.
As agreed under the terms of the financing, the 15 bond units have been converted into ordinary shares using the following conversion rate: 95% of the lowest of the five (5) daily volume weighted average Novacyt share prices (as reported by Bloomberg) immediately preceding the conversion request date of the relevant OCA ("obligation convertible en actions"), hence 1.203 euros. YA Global Master SPV Ltd. has subscribed to 124,757 shares.
Novacyt continues to monitor the conversion of the convertible bonds into shares with warrants ("obligations convertibles en actions avec bons de souscription d'action"). Additional information is available on Novacyt's website in the "Other Regulated Information" section.
– End –
About Novacyt Group
The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of clinically focused cancer and infectious disease products and services. Through its proprietary technology platform NOVAPREP®, q16 molecular platform and strong international network Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.
For more information please refer to the website: www.novacyt.com
Contacts:
International
Brett Pollard / Victoria Foster Mitchell FTI Consulting +44 (0)20 3727 1000 [email protected] / [email protected]
France
Arnaud de Cheffontaines / Astrid Villette FTI Consulting +33 (0)147 03 69 47 / +33 (0)147 03 69 51 [email protected] / [email protected]
NOVACYT
Graham Mullis Chief Executive Officer +44 (0)7901 514 121 [email protected]